Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.
作者信息
Liang Wenhua, Cai Kaican, Chen Chun, Chen Haiquan, Chen Qixun, Fu Junke, Hu Jian, Jiang Tao, Jiao Wenjie, Li Shuben, Liu Changhong, Liu Deruo, Liu Wei, Liu Yang, Ma Haitao, Pan Xiaojie, Qiao Guibin, Tian Hui, Wei Li, Zhang Yi, Zhao Song, Zhao Xiaojing, Zhou Chengzhi, Zhu Yuming, Zhong Ran, Li Feng, Rosell Rafael, Provencio Mariano, Massarelli Erminia, Antonoff Mara B, Hida Toyoaki, de Perrot Marc, Lin Steven H, Di Maio Massimo, Rossi Antonio, De Ruysscher Dirk, Ramirez Robert A, Dempke Wolfram C M, Camidge D Ross, Guibert Nicolas, Califano Raffaele, Wang Qi, Ren Shengxiang, Zhou Caicun, He Jianxing
机构信息
Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Nanfang Hospital, Guangzhou, China.
出版信息
Transl Lung Cancer Res. 2020 Dec;9(6):2696-2715. doi: 10.21037/tlcr-2020-63.
Abstract
摘要
相似文献
1
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.非小细胞肺癌新辅助免疫治疗专家共识
Transl Lung Cancer Res. 2020 Dec;9(6):2696-2715. doi: 10.21037/tlcr-2020-63.
2
The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.美国胸外科学会（AATS）2023 年专家共识文件：早期非小细胞肺癌患者的分期和多学科管理。
J Thorac Cardiovasc Surg. 2023 Sep;166(3):637-654. doi: 10.1016/j.jtcvs.2023.04.039. Epub 2023 Jun 10.
3
[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].[可切除非小细胞肺癌新辅助免疫治疗的进展]
Zhongguo Fei Ai Za Zhi. 2024 Feb 20;27(2):138-146. doi: 10.3779/j.issn.1009-3419.2024.102.06.
4
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)].《中国晚期非小细胞肺癌驱动基因变异免疫治疗专家共识（2022年版）》
Zhonghua Zhong Liu Za Zhi. 2022 Oct 23;44(10):1047-1065. doi: 10.3760/cma.j.cn112152-20220614-00416.
5
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)].《中国晚期非小细胞肺癌驱动基因变异免疫治疗专家共识（2023年版）》
Zhonghua Zhong Liu Za Zhi. 2023 Sep 23;45(9):717-740. doi: 10.3760/cma.j.cn112152-20230420-00179.
6
Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.新辅助化疗免疫治疗 II-III 期非小细胞肺癌的手术视角。
Thorac Cancer. 2021 Oct;12(20):2796-2802. doi: 10.1111/1759-7714.14127. Epub 2021 Aug 30.
7
[Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer].[非小细胞肺癌新辅助免疫治疗的进展]
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):524-533. doi: 10.3779/j.issn.1009-3419.2022.101.29.
8
Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.新辅助免疫联合化疗治疗非小细胞肺癌的疗效评价：PET/CT 与术后病理的比较。
Eur Radiol. 2023 Oct;33(10):6625-6635. doi: 10.1007/s00330-023-09922-4. Epub 2023 Jul 29.
9
[Chinese Experts Consensus on Immune Checkpoint Inhibitors
for Non-small Cell Lung Cancer (2020 Version)].《中国非小细胞肺癌免疫检查点抑制剂临床应用专家共识（2020年版）》
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):217-235. doi: 10.3779/j.issn.1009-3419.2021.101.13. Epub 2021 Apr 26.
10
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.局部晚期非小细胞肺癌（NSCLC）的多学科治疗方法：西班牙肺癌组 GECP 2023 年专家共识。
Clin Transl Oncol. 2024 Jul;26(7):1647-1663. doi: 10.1007/s12094-024-03382-y. Epub 2024 Mar 26.
引用本文的文献
1
Sirtuin family in lung adenocarcinoma.肺癌中的沉默调节蛋白家族。
Discov Oncol. 2025 Jul 23;16(1):1398. doi: 10.1007/s12672-025-03217-4.
2
Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study.新辅助治疗和手术后非小细胞肺癌的预后因素：一项回顾性观察研究
J Thorac Dis. 2025 May 30;17(5):2841-2855. doi: 10.21037/jtd-2024-1651. Epub 2025 May 27.
3
Quantitative F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST.用于预测非小细胞肺癌新辅助免疫化疗病理完全缓解的定量F-FDG PET/CT模型：与RECIST 1.1和PERCIST的比较
Eur J Nucl Med Mol Imaging. 2025 May 26. doi: 10.1007/s00259-025-07342-8.
4
Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer.新辅助化疗联合免疫治疗后单孔胸腔镜下袖状切除术治疗局部晚期中央型非小细胞肺癌的安全性和可行性分析
World J Surg Oncol. 2025 Mar 14;23(1):85. doi: 10.1186/s12957-024-03462-x.
5
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.新辅助卡博替尼治疗局部晚期非转移性透明细胞肾细胞癌：一项2期试验
Nat Cancer. 2025 Mar;6(3):432-444. doi: 10.1038/s43018-025-00922-5. Epub 2025 Feb 27.
6
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies.探索非小细胞肺癌新辅助免疫治疗的前景：进展与争议
Ther Adv Med Oncol. 2025 Jan 8;17:17588359241312501. doi: 10.1177/17588359241312501. eCollection 2025.
7
Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.癌症淋巴结转移的分子成像与靶向治疗进展：综述
J Nanobiotechnology. 2024 Dec 19;22(1):783. doi: 10.1186/s12951-024-02940-4.
8
Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy.主要病理反应可预测新辅助治疗后可切除的IIIA期非小细胞肺癌患者的生存情况。
Interdiscip Cardiovasc Thorac Surg. 2024 Dec 25;40(1). doi: 10.1093/icvts/ivae213.
9
Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.非小细胞肺癌合并慢性阻塞性肺疾病患者的新辅助免疫治疗
J Thorac Dis. 2024 Nov 30;16(11):7546-7560. doi: 10.21037/jtd-24-811. Epub 2024 Nov 8.
10
Lung autotransplantation for advanced central lung cancer after neoadjuvant immuno-chemotherapy: a case series study.新辅助免疫化疗后晚期中央型肺癌的肺自体移植：一项病例系列研究
Transl Lung Cancer Res. 2024 Nov 30;13(11):2868-2879. doi: 10.21037/tlcr-24-501. Epub 2024 Nov 18.
本文引用的文献
1
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).新辅助度伐利尤单抗治疗可切除非小细胞肺癌（NSCLC）：一项多中心研究（IFCT-1601 IONESCO）的结果。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005636.
2
Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an / Mutation.两名晚期肺腺癌患者，对纳武单抗治疗有放射学完全缓解，携带一种/突变。
JCO Precis Oncol. 2020 Nov;4:1239-1245. doi: 10.1200/PO.20.00174.
3
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌新辅助化疗联合纳武利尤单抗（NADIM）：一项开放标签、多中心、单臂、Ⅱ期临床试验。
Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24.
4
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.非小细胞肺癌的新辅助免疫治疗：现状与未来策略。
J Thorac Oncol. 2020 Aug;15(8):1281-1297. doi: 10.1016/j.jtho.2020.05.020. Epub 2020 Jun 6.
5
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.非小细胞肺癌信号通路、代谢与PD-1/PD-L1抗体
Cancers (Basel). 2020 Jun 5;12(6):1475. doi: 10.3390/cancers12061475.
6
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌患者新辅助阿替利珠单抗和化疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
7
Tumor-Associated Macrophages: Recent Insights and Therapies.肿瘤相关巨噬细胞：最新见解与治疗方法
Front Oncol. 2020 Feb 25;10:188. doi: 10.3389/fonc.2020.00188. eCollection 2020.
8
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.NOX4 抑制作用通过克服肿瘤中癌症相关成纤维细胞介导的 CD8 T 细胞排除作用增强免疫治疗。
Cancer Res. 2020 May 1;80(9):1846-1860. doi: 10.1158/0008-5472.CAN-19-3158. Epub 2020 Mar 2.
9
The efficiency of F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.F-FDG PET-CT预测可切除非小细胞肺癌新辅助PD-1阻断治疗主要病理反应的效能
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1209-1219. doi: 10.1007/s00259-020-04711-3. Epub 2020 Feb 11.
10
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.新辅助 PD-1 抑制剂（信迪利单抗）治疗 NSCLC。
J Thorac Oncol. 2020 May;15(5):816-826. doi: 10.1016/j.jtho.2020.01.017. Epub 2020 Feb 6.
Zotero 插件